CYTK Stock Analysis: Cytokinetics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.159m USD | 12M Return: 157.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 162M
Qual. Beats: 0
Rev. Trend: 80.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Cytokinetics, Incorporated (NASDAQ: CYTK) is a biopharmaceutical company founded in 1997 and headquartered in South San Francisco, California. The company focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases, with a particular emphasis on cardiovascular conditions.
The companys commercial product, MYQORZO, is an oral small molecule cardiac myosin inhibitor approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Its clinical pipeline includes Aficamten, another cardiac myosin inhibitor in development for HCM, and omecamtiv mecarbil, a treatment candidate for heart failure with severely reduced ejection fraction. Earlier-stage programs include Ulacamten (Phase 1) for heart failure with preserved ejection fraction and CK-089 (Phase 1), a fast skeletal muscle troponin activator.
As a clinical-stage and commercial biotechnology company, Cytokinetics operates in a sector characterized by lengthy R&D timelines, significant clinical trial costs, and reliance on regulatory approvals from the U.S. Food and Drug Administration. The companys pipeline targets areas of substantial unmet medical need, particularly hypertrophic cardiomyopathy and various forms of heart failure, where limited treatment options have historically existed. Cytokinetics completed its IPO on April 29, 2004, and is classified within the Health Care sector under the Biotechnology sub-industry.
- MYQORZO launch trajectory drives near-term commercial revenue growth
- Aficamten FDA approval decision expands HCM market opportunity
- Competition from Camzyos pressures cardiac myosin inhibitor market share
| Net Income: -829.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -15.96 > 1.0 |
| NWC/Revenue: 605.1% < 20% (prev 4.14k%; Δ -3.54k% < -1%) |
| CFO/TA -0.41 > 3% & CFO -523.8m > Net Income -829.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.21 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.3m) vs 12m ago 4.03% < -2% |
| Gross Margin: 90.34% > 18% (prev -1.76k%; Δ 1.85k% > 0.5%) |
| Asset Turnover: 8.34% > 50% (prev 1.52%; Δ 6.82% > 0%) |
| Interest Coverage Ratio: -6.53 > 6 (EBIT TTM -745.7m / Interest Expense TTM 114.3m) |
| A: 0.50 (Total Current Assets 839.5m - Total Current Liabilities 199.2m) / Total Assets 1.27b |
| B: -2.90 (Retained Earnings -3.69b / Total Assets 1.27b) |
| C: -0.59 (EBIT TTM -745.7m / Avg Total Assets 1.27b) |
| D: -0.39 (Book Value of Equity -826.6m / Total Liabilities 2.10b) |
| Altman-Z'' = -10.52 = D |
| DSRI: 0.62 (Receivables 6.83m/2.01m, Revenue 105.8m/19.2m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.68 (AQ_t 0.22 / AQ_t-1 0.13) |
| SGI: 5.51 (Revenue 105.8m / 19.2m) |
| TATA: -0.24 (NI -829.6m - CFO -523.8m) / TA 1.27b) |
| Beneish M = 0.27 (Cap -4..+1) = D |
As of July 01, 2026, the stock is trading at USD 85.19 with a total of 2,403,843 shares traded. Over the past week, the price has changed by +6.47%, over one month by +15.62%, over three months by +29.25% and over the past year by +157.84%.
Current recommended Stop Loss: 76.60 (which is 10.1% or 2.5 ATR below the current price).
Cytokinetics has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CYTK.
- StrongBuy: 9
- Buy: 9
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 105.6 | 24% |
P/E Forward = 117.6471
P/S = 105.4575
P/B = 60.3093
P/EG = -0.42
Revenue TTM = 105.8m USD
EBIT TTM = -745.7m USD
EBITDA TTM = -734.7m USD
Long Term Debt = 1.12b USD (from longTermDebt, last quarter)
Short Term Debt = 65.8m USD (from shortTermDebt, last quarter)
Debt = 1.41b USD (from shortLongTermDebtTotal, last quarter) + Leases 126.2m
Net Debt = 952.8m USD (calculated: Debt 1.41b - CCE 462.2m)
Enterprise Value = 12.1b USD (11.2b + Debt 1.41b - CCE 462.2m)
Interest Coverage Ratio = -6.53 (Ebit TTM -745.7m / Interest Expense TTM 114.3m)
EV/FCF = -16.72x (Enterprise Value 12.1b / FCF TTM -724.3m)
FCF Yield = -5.98% (FCF TTM -724.3m / Enterprise Value 12.1b)
FCF Margin = -684.5% (FCF TTM -724.3m / Revenue TTM 105.8m)
Net Margin = -784.0% (Net Income TTM -829.6m / Revenue TTM 105.8m)
Gross Margin = 90.34% ((Revenue TTM 105.8m - Cost of Revenue TTM 10.2m) / Revenue TTM)
Gross Margin QoQ = 87.64% (prev 83.89%)
Tobins Q-Ratio = 9.51 (Enterprise Value 12.1b / Total Assets 1.27b)
Interest Expense / Debt = 8.08% (Interest Expense 114.3m / Debt 1.41b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -589.1m (EBIT -745.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.75 (Total Current Assets 839.5m / Total Current Liabilities 223.9m)
Debt / Equity = -1.71 (negative equity) (Debt 1.41b / totalStockholderEquity, last quarter -826.6m)
Debt / EBITDA = -1.30 (negative EBITDA) (Net Debt 952.8m / EBITDA -734.7m)
Debt / FCF = -1.32 (negative FCF - burning cash) (Net Debt 952.8m / FCF TTM -724.3m)
Total Stockholder Equity = -594.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -65.39% (Net Income -829.6m / Total Assets 1.27b)
RoE = 139.7% (negative equity) (Net Income TTM -829.6m / Total Stockholder Equity -594.0m)
RoCE = -142.4% (out of range, set to none) (EBIT -745.7m / Capital Employed (Equity -594.0m + L.T.Debt 1.12b))
RoIC = -51.91% (negative operating profit) (NOPAT -589.1m / Invested Capital 1.13b)
WACC = 9.78% (E(11.2b)/V(12.6b) * Re(10.21%) + D(1.41b)/V(12.6b) * Rd(8.08%) * (1-Tc(0.21)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.20%
[DCF] Fair Price = unknown (Cash Flow -724.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.11 | # QB: 0
Revenue Correlation: 80.42 | Revenue CAGR: 241.3% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-09-30): EPS=-1.57 | Chg30d=+1.45% | Revisions=+29% | Analysts=16
EPS current Year (2026-12-31): EPS=-6.35 | Chg30d=+1.36% | Revisions=+18% | GrowthEPS=+3.0% | GrowthRev=+23.2%
EPS next Year (2027-12-31): EPS=-4.67 | Chg30d=+1.76% | Revisions=+25% | GrowthEPS=+26.4% | GrowthRev=+258.3%
[Analyst] Revisions Ratio: +29%